Overview

A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus

Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of rontalizumab compared with placebo in patients with moderately to severely active systemic lupus erythematosus (SLE).
Phase:
Phase 2
Details
Lead Sponsor:
Genentech, Inc.